Hims & Hers Health (NYSE:HIMS) Insider Soleil Boughton Sells 4,812 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 4,812 shares of the firm’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $24.69, for a total value of $118,808.28. Following the completion of the sale, the insider directly owned 308,831 shares of the company’s stock, valued at approximately $7,625,037.39. This trade represents a 1.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Hims & Hers Health Stock Up 0.6%

NYSE:HIMS traded up $0.14 during trading hours on Thursday, hitting $23.29. 4,119,365 shares of the company’s stock traded hands, compared to its average volume of 35,008,840. The stock’s fifty day moving average price is $23.19 and its two-hundred day moving average price is $36.98. The firm has a market cap of $5.31 billion, a P/E ratio of 45.51, a P/E/G ratio of 2.80 and a beta of 2.55. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.70 and a current ratio of 1.90. Hims & Hers Health, Inc. has a twelve month low of $13.74 and a twelve month high of $70.43.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, February 23rd. The company reported $0.08 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.06. The firm had revenue of $617.82 million during the quarter, compared to analyst estimates of $619.48 million. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The business’s quarterly revenue was up 28.4% compared to the same quarter last year. During the same period last year, the company posted $0.11 EPS. On average, research analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

HIMS has been the subject of a number of research analyst reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Hims & Hers Health in a research report on Monday, December 29th. Needham & Company LLC raised shares of Hims & Hers Health from a “hold” rating to a “buy” rating and set a $30.00 price target on the stock in a research note on Monday, March 9th. Evercore set a $24.00 price objective on Hims & Hers Health in a report on Tuesday, February 24th. Truist Financial reissued a “hold” rating and set a $18.00 price objective (down from $37.00) on shares of Hims & Hers Health in a research report on Tuesday, February 24th. Finally, Leerink Partners upped their target price on Hims & Hers Health from $17.50 to $25.00 and gave the stock a “market perform” rating in a research report on Monday. Three investment analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $31.29.

Hims & Hers Health News Roundup

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Partnership win — HIMS reached an agreement with Novo Nordisk to offer Ozempic and Wegovy via its telehealth platform and has opened a pre‑launch waitlist, which could meaningfully expand prescription volume and subscription revenue if adoption scales. Novo Nordisk Partners With Hims & Hers — Yahoo Finance
• Positive Sentiment: Sell‑side support — at least one research note and other analyst commentary point to upside for HIMS tied to GLP‑1 access and growth execution, which can help medium‑term investor confidence if operational metrics follow. Leerink Forecasts Strong Price Appreciation — AmericanBankingNews
• Neutral Sentiment: Industry context — broader coverage and value‑investing pieces are highlighting HIMS among telehealth/weight‑loss beneficiaries; useful background but not an immediate catalyst on its own. Seeking Alpha: Value Investing With Raul Shah
• Negative Sentiment: Significant insider selling — COO Michael Chi disclosed the sale of ~97k shares (SEC Form 4), and other insiders also sold smaller stakes on March 17. Large insider dispositions can pressure sentiment and signal liquidity taking or reduced near‑term conviction. SEC Form 4 — Michael Chi
• Negative Sentiment: GLP‑1 pricing risk — analysts warn increasing price competition between Novo Nordisk and Eli Lilly could drive faster discounting, which would compress gross margins and ARPU for telehealth distributors. Health Care Roundup — Yahoo Finance
• Negative Sentiment: Short‑term market reaction — trade reports show HIMS underperformed the broader market in the most recent session, reflecting immediate selling pressure despite the strategic news. Zacks — HIMS Suffers Larger Drop

Hedge Funds Weigh In On Hims & Hers Health

Several hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. raised its holdings in Hims & Hers Health by 7.2% during the fourth quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock valued at $679,456,000 after buying an additional 1,407,651 shares in the last quarter. Capital World Investors boosted its stake in shares of Hims & Hers Health by 1.2% during the 3rd quarter. Capital World Investors now owns 18,783,194 shares of the company’s stock worth $1,065,399,000 after acquiring an additional 223,892 shares in the last quarter. Farallon Capital Management LLC increased its holdings in shares of Hims & Hers Health by 30.8% during the 3rd quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock valued at $609,561,000 after acquiring an additional 2,533,271 shares during the last quarter. State Street Corp raised its stake in shares of Hims & Hers Health by 1.8% in the 4th quarter. State Street Corp now owns 7,305,525 shares of the company’s stock valued at $237,210,000 after acquiring an additional 132,311 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Hims & Hers Health by 12.4% in the 4th quarter. Geode Capital Management LLC now owns 5,509,764 shares of the company’s stock worth $183,485,000 after purchasing an additional 608,950 shares during the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.